Interim Results Indicate Progress in Phase 3 ENSURE Program of Vidofludimus Calcium

2 min read | October 22, 2024 10:06 PM AEDT | By Team Kalkine Media

Google News:

Interim Results Indicate Progress in Phase 3 ENSURE Program of Vidofludimus Calcium — Image source: Shutterstock

Recent News

Gold Sparks Mining Rebound as ASX Giants Wake

Iron Ore Giants Adjust as Simandou Reshapes Market

ASX Mining Dividends: Fortescue vs Rio Tinto vs BHP

Lithium Stocks Ignite as ASX Battery Boom Returns

Make Kalkine Media
My Trusted Source

Highlights

Immunic, Inc. received a positive recommendation from the Independent Data Monitoring Committee for its phase 3 ENSURE program, assessing vidofludimus calcium for relapsing multiple sclerosis.

The ENSURE program remains on schedule for completion in 2026, with trial designs aligned with observed data.

The trial consists of two identical phase 3 studies, each enrolling approximately 1,050 adult patients with relapsing multiple sclerosis.

Immunic, Inc. (NASDAQ:IMUX) has announced a positive outcome from the interim futility analysis of its phase 3 ENSURE program, which evaluates vidofludimus calcium as a treatment for relapsing multiple sclerosis (RMS). An Independent Data Monitoring Committee (IDMC) conducted the analysis and determined that the predetermined futility criteria were not met, thus recommending that the trials proceed without any changes.

This affirmation is significant as it indicates that the trial design and assumptions align with the data observed thus far, supporting the continuation of the program. Immunic remains blinded to all data, ensuring the integrity of the ongoing trials.

The ENSURE program comprises two identical phase 3 trials, each enrolling around 1,050 adult patients diagnosed with RMS. The primary endpoint of these trials is the time to first relapse, assessed over a period of up to 72 weeks. The completion timeline for the ENSURE-1 trial is projected for the second quarter of 2026, while ENSURE-2 is expected to conclude in the second half of 2026.

These developments signify a crucial step forward for Immunic as it works to advance its clinical program in the treatment of RMS. The positive recommendation from the IDMC not only validates the design of the ENSURE program but also bolsters confidence in the potential of vidofludimus calcium as a therapeutic option for patients suffering from this chronic neurological condition. The ongoing commitment to rigorous clinical evaluation underscores Immunic's dedication to developing effective treatments that could enhance patient outcomes in multiple sclerosis.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.